Global Thrombolysis Market
Global Thrombolysis Market

Thrombolysis Comprehensive Study by Type (Surgical Treatment, Drug Treatment, Other Treatment), Application (Pulmonary Embolism, Deep Vein Thrombosis, Acute Myocardial Infarction, Blocking the Catheter, Acute Ischemic Stroke, Other), End Use (Hospitals, Ambulatory Surgical Centres) Players and Region - Global Market Outlook to 2025

Thrombolysis Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 219 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Thrombolysis Market Study:
Roche (Switzerland), Boehringer Ingelheim (Germany), Mochida Pharmaceutical (Japan), Tianjin Biochem Pharmaceutical (China), Livzon Pharmaceutical Group (China), Sedico Pharmaceuticals (Egypt), Microbix (Canada), Angiodynamics, Inc. (United States), Argon Medical Devices Inc. (United States), Athersys, Inc. (United States) and Glaxosmithkline Plc (United Kingdom)

In the last few years, Global market of Thrombolysis developed rapidly. Major factors driving the market are Increase in the Number of Blood Clots Problem Among People.

On the basis of product type, the Thrombolysis market is segmented by Surgical Treatment, Drug Treatment and Other Treatment.

On the basis of applications, the Thrombolysis market is segmented by Pulmonary Embolism, Deep Vein Thrombosis, Acute Myocardial Infarction, Blocking the Catheter, Acute Ischemic Stroke and Other.

Some of the other players that are also part of study are Boston Scientific Corporation, Medtronic Plc, Teva Pharmaceutical Industries Ltd. and Straub Medical AG. The Global Thrombolysis market is gaining huge competition due to involvement of Chinese and United States companies that constantly invest in research & development to meet market expectation with new innovation.

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Thrombolysis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Thrombolysis market.
Identification of total players or companies operating in the global market which is further concentrated to a fewer or most impacting players which is considered under the reportís scope. In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Providers of Postoperative Pain Therapeutics, End-Users, Potential Investors, Regulatory Bodies, Market Research Firms and Others.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Surgical Treatment
  • Drug Treatment
  • Other Treatment
By Application
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Acute Myocardial Infarction
  • Blocking the Catheter
  • Acute Ischemic Stroke
  • Other
By End Use
  • Hospitals
  • Ambulatory Surgical Centres

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Number of Blood Clots Problem Among People
    • 3.3. Market Challenges
      • 3.3.1. Short-term Challenges due to Reduced Operations Across Different Industries & Economic Crisis caused by COVID-19 Pandemic Across the World
    • 3.4. Market Trends
      • 3.4.1. Changing Healthcare Scenario and Advancement in Medical Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Thrombolysis, by Type, Application, End Use and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Thrombolysis (Value)
      • 5.2.1. Global Thrombolysis by: Type (Value)
        • 5.2.1.1. Surgical Treatment
        • 5.2.1.2. Drug Treatment
        • 5.2.1.3. Other Treatment
      • 5.2.2. Global Thrombolysis by: Application (Value)
        • 5.2.2.1. Pulmonary Embolism
        • 5.2.2.2. Deep Vein Thrombosis
        • 5.2.2.3. Acute Myocardial Infarction
        • 5.2.2.4. Blocking the Catheter
        • 5.2.2.5. Acute Ischemic Stroke
        • 5.2.2.6. Other
      • 5.2.3. Global Thrombolysis by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Centres
      • 5.2.4. Global Thrombolysis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Thrombolysis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mochida Pharmaceutical (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Tianjin Biochem Pharmaceutical (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Livzon Pharmaceutical Group (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sedico Pharmaceuticals (Egypt)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Microbix (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Angiodynamics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Argon Medical Devices Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Athersys, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Glaxosmithkline Plc (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Thrombolysis Sale, by Type, Application, End Use and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Thrombolysis (Value)
      • 7.2.1. Global Thrombolysis by: Type (Value)
        • 7.2.1.1. Surgical Treatment
        • 7.2.1.2. Drug Treatment
        • 7.2.1.3. Other Treatment
      • 7.2.2. Global Thrombolysis by: Application (Value)
        • 7.2.2.1. Pulmonary Embolism
        • 7.2.2.2. Deep Vein Thrombosis
        • 7.2.2.3. Acute Myocardial Infarction
        • 7.2.2.4. Blocking the Catheter
        • 7.2.2.5. Acute Ischemic Stroke
        • 7.2.2.6. Other
      • 7.2.3. Global Thrombolysis by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Centres
      • 7.2.4. Global Thrombolysis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Thrombolysis: by Type(USD Million)
  • Table 2. Thrombolysis Surgical Treatment , by Region USD Million (2014-2019)
  • Table 3. Thrombolysis Drug Treatment , by Region USD Million (2014-2019)
  • Table 4. Thrombolysis Other Treatment , by Region USD Million (2014-2019)
  • Table 5. Thrombolysis: by Application(USD Million)
  • Table 6. Thrombolysis Pulmonary Embolism , by Region USD Million (2014-2019)
  • Table 7. Thrombolysis Deep Vein Thrombosis , by Region USD Million (2014-2019)
  • Table 8. Thrombolysis Acute Myocardial Infarction , by Region USD Million (2014-2019)
  • Table 9. Thrombolysis Blocking the Catheter , by Region USD Million (2014-2019)
  • Table 10. Thrombolysis Acute Ischemic Stroke , by Region USD Million (2014-2019)
  • Table 11. Thrombolysis Other , by Region USD Million (2014-2019)
  • Table 12. Thrombolysis: by End Use(USD Million)
  • Table 13. Thrombolysis Hospitals , by Region USD Million (2014-2019)
  • Table 14. Thrombolysis Ambulatory Surgical Centres , by Region USD Million (2014-2019)
  • Table 15. South America Thrombolysis, by Country USD Million (2014-2019)
  • Table 16. South America Thrombolysis, by Type USD Million (2014-2019)
  • Table 17. South America Thrombolysis, by Application USD Million (2014-2019)
  • Table 18. South America Thrombolysis, by End Use USD Million (2014-2019)
  • Table 19. Brazil Thrombolysis, by Type USD Million (2014-2019)
  • Table 20. Brazil Thrombolysis, by Application USD Million (2014-2019)
  • Table 21. Brazil Thrombolysis, by End Use USD Million (2014-2019)
  • Table 22. Argentina Thrombolysis, by Type USD Million (2014-2019)
  • Table 23. Argentina Thrombolysis, by Application USD Million (2014-2019)
  • Table 24. Argentina Thrombolysis, by End Use USD Million (2014-2019)
  • Table 25. Rest of South America Thrombolysis, by Type USD Million (2014-2019)
  • Table 26. Rest of South America Thrombolysis, by Application USD Million (2014-2019)
  • Table 27. Rest of South America Thrombolysis, by End Use USD Million (2014-2019)
  • Table 28. Asia Pacific Thrombolysis, by Country USD Million (2014-2019)
  • Table 29. Asia Pacific Thrombolysis, by Type USD Million (2014-2019)
  • Table 30. Asia Pacific Thrombolysis, by Application USD Million (2014-2019)
  • Table 31. Asia Pacific Thrombolysis, by End Use USD Million (2014-2019)
  • Table 32. China Thrombolysis, by Type USD Million (2014-2019)
  • Table 33. China Thrombolysis, by Application USD Million (2014-2019)
  • Table 34. China Thrombolysis, by End Use USD Million (2014-2019)
  • Table 35. Japan Thrombolysis, by Type USD Million (2014-2019)
  • Table 36. Japan Thrombolysis, by Application USD Million (2014-2019)
  • Table 37. Japan Thrombolysis, by End Use USD Million (2014-2019)
  • Table 38. India Thrombolysis, by Type USD Million (2014-2019)
  • Table 39. India Thrombolysis, by Application USD Million (2014-2019)
  • Table 40. India Thrombolysis, by End Use USD Million (2014-2019)
  • Table 41. South Korea Thrombolysis, by Type USD Million (2014-2019)
  • Table 42. South Korea Thrombolysis, by Application USD Million (2014-2019)
  • Table 43. South Korea Thrombolysis, by End Use USD Million (2014-2019)
  • Table 44. Taiwan Thrombolysis, by Type USD Million (2014-2019)
  • Table 45. Taiwan Thrombolysis, by Application USD Million (2014-2019)
  • Table 46. Taiwan Thrombolysis, by End Use USD Million (2014-2019)
  • Table 47. Australia Thrombolysis, by Type USD Million (2014-2019)
  • Table 48. Australia Thrombolysis, by Application USD Million (2014-2019)
  • Table 49. Australia Thrombolysis, by End Use USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Thrombolysis, by Type USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Thrombolysis, by Application USD Million (2014-2019)
  • Table 52. Rest of Asia-Pacific Thrombolysis, by End Use USD Million (2014-2019)
  • Table 53. Europe Thrombolysis, by Country USD Million (2014-2019)
  • Table 54. Europe Thrombolysis, by Type USD Million (2014-2019)
  • Table 55. Europe Thrombolysis, by Application USD Million (2014-2019)
  • Table 56. Europe Thrombolysis, by End Use USD Million (2014-2019)
  • Table 57. Germany Thrombolysis, by Type USD Million (2014-2019)
  • Table 58. Germany Thrombolysis, by Application USD Million (2014-2019)
  • Table 59. Germany Thrombolysis, by End Use USD Million (2014-2019)
  • Table 60. France Thrombolysis, by Type USD Million (2014-2019)
  • Table 61. France Thrombolysis, by Application USD Million (2014-2019)
  • Table 62. France Thrombolysis, by End Use USD Million (2014-2019)
  • Table 63. Italy Thrombolysis, by Type USD Million (2014-2019)
  • Table 64. Italy Thrombolysis, by Application USD Million (2014-2019)
  • Table 65. Italy Thrombolysis, by End Use USD Million (2014-2019)
  • Table 66. United Kingdom Thrombolysis, by Type USD Million (2014-2019)
  • Table 67. United Kingdom Thrombolysis, by Application USD Million (2014-2019)
  • Table 68. United Kingdom Thrombolysis, by End Use USD Million (2014-2019)
  • Table 69. Netherlands Thrombolysis, by Type USD Million (2014-2019)
  • Table 70. Netherlands Thrombolysis, by Application USD Million (2014-2019)
  • Table 71. Netherlands Thrombolysis, by End Use USD Million (2014-2019)
  • Table 72. Rest of Europe Thrombolysis, by Type USD Million (2014-2019)
  • Table 73. Rest of Europe Thrombolysis, by Application USD Million (2014-2019)
  • Table 74. Rest of Europe Thrombolysis, by End Use USD Million (2014-2019)
  • Table 75. MEA Thrombolysis, by Country USD Million (2014-2019)
  • Table 76. MEA Thrombolysis, by Type USD Million (2014-2019)
  • Table 77. MEA Thrombolysis, by Application USD Million (2014-2019)
  • Table 78. MEA Thrombolysis, by End Use USD Million (2014-2019)
  • Table 79. Middle East Thrombolysis, by Type USD Million (2014-2019)
  • Table 80. Middle East Thrombolysis, by Application USD Million (2014-2019)
  • Table 81. Middle East Thrombolysis, by End Use USD Million (2014-2019)
  • Table 82. Africa Thrombolysis, by Type USD Million (2014-2019)
  • Table 83. Africa Thrombolysis, by Application USD Million (2014-2019)
  • Table 84. Africa Thrombolysis, by End Use USD Million (2014-2019)
  • Table 85. North America Thrombolysis, by Country USD Million (2014-2019)
  • Table 86. North America Thrombolysis, by Type USD Million (2014-2019)
  • Table 87. North America Thrombolysis, by Application USD Million (2014-2019)
  • Table 88. North America Thrombolysis, by End Use USD Million (2014-2019)
  • Table 89. United States Thrombolysis, by Type USD Million (2014-2019)
  • Table 90. United States Thrombolysis, by Application USD Million (2014-2019)
  • Table 91. United States Thrombolysis, by End Use USD Million (2014-2019)
  • Table 92. Canada Thrombolysis, by Type USD Million (2014-2019)
  • Table 93. Canada Thrombolysis, by Application USD Million (2014-2019)
  • Table 94. Canada Thrombolysis, by End Use USD Million (2014-2019)
  • Table 95. Mexico Thrombolysis, by Type USD Million (2014-2019)
  • Table 96. Mexico Thrombolysis, by Application USD Million (2014-2019)
  • Table 97. Mexico Thrombolysis, by End Use USD Million (2014-2019)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Thrombolysis: by Type(USD Million)
  • Table 110. Thrombolysis Surgical Treatment , by Region USD Million (2020-2025)
  • Table 111. Thrombolysis Drug Treatment , by Region USD Million (2020-2025)
  • Table 112. Thrombolysis Other Treatment , by Region USD Million (2020-2025)
  • Table 113. Thrombolysis: by Application(USD Million)
  • Table 114. Thrombolysis Pulmonary Embolism , by Region USD Million (2020-2025)
  • Table 115. Thrombolysis Deep Vein Thrombosis , by Region USD Million (2020-2025)
  • Table 116. Thrombolysis Acute Myocardial Infarction , by Region USD Million (2020-2025)
  • Table 117. Thrombolysis Blocking the Catheter , by Region USD Million (2020-2025)
  • Table 118. Thrombolysis Acute Ischemic Stroke , by Region USD Million (2020-2025)
  • Table 119. Thrombolysis Other , by Region USD Million (2020-2025)
  • Table 120. Thrombolysis: by End Use(USD Million)
  • Table 121. Thrombolysis Hospitals , by Region USD Million (2020-2025)
  • Table 122. Thrombolysis Ambulatory Surgical Centres , by Region USD Million (2020-2025)
  • Table 123. South America Thrombolysis, by Country USD Million (2020-2025)
  • Table 124. South America Thrombolysis, by Type USD Million (2020-2025)
  • Table 125. South America Thrombolysis, by Application USD Million (2020-2025)
  • Table 126. South America Thrombolysis, by End Use USD Million (2020-2025)
  • Table 127. Brazil Thrombolysis, by Type USD Million (2020-2025)
  • Table 128. Brazil Thrombolysis, by Application USD Million (2020-2025)
  • Table 129. Brazil Thrombolysis, by End Use USD Million (2020-2025)
  • Table 130. Argentina Thrombolysis, by Type USD Million (2020-2025)
  • Table 131. Argentina Thrombolysis, by Application USD Million (2020-2025)
  • Table 132. Argentina Thrombolysis, by End Use USD Million (2020-2025)
  • Table 133. Rest of South America Thrombolysis, by Type USD Million (2020-2025)
  • Table 134. Rest of South America Thrombolysis, by Application USD Million (2020-2025)
  • Table 135. Rest of South America Thrombolysis, by End Use USD Million (2020-2025)
  • Table 136. Asia Pacific Thrombolysis, by Country USD Million (2020-2025)
  • Table 137. Asia Pacific Thrombolysis, by Type USD Million (2020-2025)
  • Table 138. Asia Pacific Thrombolysis, by Application USD Million (2020-2025)
  • Table 139. Asia Pacific Thrombolysis, by End Use USD Million (2020-2025)
  • Table 140. China Thrombolysis, by Type USD Million (2020-2025)
  • Table 141. China Thrombolysis, by Application USD Million (2020-2025)
  • Table 142. China Thrombolysis, by End Use USD Million (2020-2025)
  • Table 143. Japan Thrombolysis, by Type USD Million (2020-2025)
  • Table 144. Japan Thrombolysis, by Application USD Million (2020-2025)
  • Table 145. Japan Thrombolysis, by End Use USD Million (2020-2025)
  • Table 146. India Thrombolysis, by Type USD Million (2020-2025)
  • Table 147. India Thrombolysis, by Application USD Million (2020-2025)
  • Table 148. India Thrombolysis, by End Use USD Million (2020-2025)
  • Table 149. South Korea Thrombolysis, by Type USD Million (2020-2025)
  • Table 150. South Korea Thrombolysis, by Application USD Million (2020-2025)
  • Table 151. South Korea Thrombolysis, by End Use USD Million (2020-2025)
  • Table 152. Taiwan Thrombolysis, by Type USD Million (2020-2025)
  • Table 153. Taiwan Thrombolysis, by Application USD Million (2020-2025)
  • Table 154. Taiwan Thrombolysis, by End Use USD Million (2020-2025)
  • Table 155. Australia Thrombolysis, by Type USD Million (2020-2025)
  • Table 156. Australia Thrombolysis, by Application USD Million (2020-2025)
  • Table 157. Australia Thrombolysis, by End Use USD Million (2020-2025)
  • Table 158. Rest of Asia-Pacific Thrombolysis, by Type USD Million (2020-2025)
  • Table 159. Rest of Asia-Pacific Thrombolysis, by Application USD Million (2020-2025)
  • Table 160. Rest of Asia-Pacific Thrombolysis, by End Use USD Million (2020-2025)
  • Table 161. Europe Thrombolysis, by Country USD Million (2020-2025)
  • Table 162. Europe Thrombolysis, by Type USD Million (2020-2025)
  • Table 163. Europe Thrombolysis, by Application USD Million (2020-2025)
  • Table 164. Europe Thrombolysis, by End Use USD Million (2020-2025)
  • Table 165. Germany Thrombolysis, by Type USD Million (2020-2025)
  • Table 166. Germany Thrombolysis, by Application USD Million (2020-2025)
  • Table 167. Germany Thrombolysis, by End Use USD Million (2020-2025)
  • Table 168. France Thrombolysis, by Type USD Million (2020-2025)
  • Table 169. France Thrombolysis, by Application USD Million (2020-2025)
  • Table 170. France Thrombolysis, by End Use USD Million (2020-2025)
  • Table 171. Italy Thrombolysis, by Type USD Million (2020-2025)
  • Table 172. Italy Thrombolysis, by Application USD Million (2020-2025)
  • Table 173. Italy Thrombolysis, by End Use USD Million (2020-2025)
  • Table 174. United Kingdom Thrombolysis, by Type USD Million (2020-2025)
  • Table 175. United Kingdom Thrombolysis, by Application USD Million (2020-2025)
  • Table 176. United Kingdom Thrombolysis, by End Use USD Million (2020-2025)
  • Table 177. Netherlands Thrombolysis, by Type USD Million (2020-2025)
  • Table 178. Netherlands Thrombolysis, by Application USD Million (2020-2025)
  • Table 179. Netherlands Thrombolysis, by End Use USD Million (2020-2025)
  • Table 180. Rest of Europe Thrombolysis, by Type USD Million (2020-2025)
  • Table 181. Rest of Europe Thrombolysis, by Application USD Million (2020-2025)
  • Table 182. Rest of Europe Thrombolysis, by End Use USD Million (2020-2025)
  • Table 183. MEA Thrombolysis, by Country USD Million (2020-2025)
  • Table 184. MEA Thrombolysis, by Type USD Million (2020-2025)
  • Table 185. MEA Thrombolysis, by Application USD Million (2020-2025)
  • Table 186. MEA Thrombolysis, by End Use USD Million (2020-2025)
  • Table 187. Middle East Thrombolysis, by Type USD Million (2020-2025)
  • Table 188. Middle East Thrombolysis, by Application USD Million (2020-2025)
  • Table 189. Middle East Thrombolysis, by End Use USD Million (2020-2025)
  • Table 190. Africa Thrombolysis, by Type USD Million (2020-2025)
  • Table 191. Africa Thrombolysis, by Application USD Million (2020-2025)
  • Table 192. Africa Thrombolysis, by End Use USD Million (2020-2025)
  • Table 193. North America Thrombolysis, by Country USD Million (2020-2025)
  • Table 194. North America Thrombolysis, by Type USD Million (2020-2025)
  • Table 195. North America Thrombolysis, by Application USD Million (2020-2025)
  • Table 196. North America Thrombolysis, by End Use USD Million (2020-2025)
  • Table 197. United States Thrombolysis, by Type USD Million (2020-2025)
  • Table 198. United States Thrombolysis, by Application USD Million (2020-2025)
  • Table 199. United States Thrombolysis, by End Use USD Million (2020-2025)
  • Table 200. Canada Thrombolysis, by Type USD Million (2020-2025)
  • Table 201. Canada Thrombolysis, by Application USD Million (2020-2025)
  • Table 202. Canada Thrombolysis, by End Use USD Million (2020-2025)
  • Table 203. Mexico Thrombolysis, by Type USD Million (2020-2025)
  • Table 204. Mexico Thrombolysis, by Application USD Million (2020-2025)
  • Table 205. Mexico Thrombolysis, by End Use USD Million (2020-2025)
  • Table 206. Research Programs/Design for This Report
  • Table 207. Key Data Information from Secondary Sources
  • Table 208. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Thrombolysis: by Type USD Million (2014-2019)
  • Figure 5. Global Thrombolysis: by Application USD Million (2014-2019)
  • Figure 6. Global Thrombolysis: by End Use USD Million (2014-2019)
  • Figure 7. South America Thrombolysis Share (%), by Country
  • Figure 8. Asia Pacific Thrombolysis Share (%), by Country
  • Figure 9. Europe Thrombolysis Share (%), by Country
  • Figure 10. MEA Thrombolysis Share (%), by Country
  • Figure 11. North America Thrombolysis Share (%), by Country
  • Figure 12. Global Thrombolysis share by Players 2019 (%)
  • Figure 13. Global Thrombolysis share by Players (Top 3) 2019(%)
  • Figure 14. Global Thrombolysis share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Roche (Switzerland) Revenue: by Geography 2019
  • Figure 18. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Boehringer Ingelheim (Germany) Revenue: by Geography 2019
  • Figure 20. Mochida Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Mochida Pharmaceutical (Japan) Revenue: by Geography 2019
  • Figure 22. Tianjin Biochem Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 23. Tianjin Biochem Pharmaceutical (China) Revenue: by Geography 2019
  • Figure 24. Livzon Pharmaceutical Group (China) Revenue, Net Income and Gross profit
  • Figure 25. Livzon Pharmaceutical Group (China) Revenue: by Geography 2019
  • Figure 26. Sedico Pharmaceuticals (Egypt) Revenue, Net Income and Gross profit
  • Figure 27. Sedico Pharmaceuticals (Egypt) Revenue: by Geography 2019
  • Figure 28. Microbix (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Microbix (Canada) Revenue: by Geography 2019
  • Figure 30. Angiodynamics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Angiodynamics, Inc. (United States) Revenue: by Geography 2019
  • Figure 32. Argon Medical Devices Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Argon Medical Devices Inc. (United States) Revenue: by Geography 2019
  • Figure 34. Athersys, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Athersys, Inc. (United States) Revenue: by Geography 2019
  • Figure 36. Glaxosmithkline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Glaxosmithkline Plc (United Kingdom) Revenue: by Geography 2019
  • Figure 38. Global Thrombolysis: by Type USD Million (2020-2025)
  • Figure 39. Global Thrombolysis: by Application USD Million (2020-2025)
  • Figure 40. Global Thrombolysis: by End Use USD Million (2020-2025)
  • Figure 41. South America Thrombolysis Share (%), by Country
  • Figure 42. Asia Pacific Thrombolysis Share (%), by Country
  • Figure 43. Europe Thrombolysis Share (%), by Country
  • Figure 44. MEA Thrombolysis Share (%), by Country
  • Figure 45. North America Thrombolysis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Roche (Switzerland)
  • Boehringer Ingelheim (Germany)
  • Mochida Pharmaceutical (Japan)
  • Tianjin Biochem Pharmaceutical (China)
  • Livzon Pharmaceutical Group (China)
  • Sedico Pharmaceuticals (Egypt)
  • Microbix (Canada)
  • Angiodynamics, Inc. (United States)
  • Argon Medical Devices Inc. (United States)
  • Athersys, Inc. (United States)
  • Glaxosmithkline Plc (United Kingdom)
Additional players considered in the study are as follows:
Boston Scientific Corporation , Medtronic Plc , Teva Pharmaceutical Industries Ltd. , Straub Medical AG
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation